Artificial Insemination Market (By Type Outlook: Intravaginal, Intracervical, Intrauterine, Intratubal; By End Use: Home, Fertility Clinics & Other Facilities; By Source Type: AID-Donor, AIH-Husband) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

According to Acumen Research and Consulting, the global artificial insemination market size is poised to reach around US$ 3.0 billion by 2026, at noteworthy CAGR around 8 % over the forecast period 2019 to 2026.

Artificial insemination is a fertilization operation involving the use of a syringe to place sperm into the female's reproductive tract. Artificial insemination is the way sperm with a sample cup and a sterile syringe is artificially inseminated. This technique is often appropriate for single females, lesbian pairs and infertile pairs. Artificial insemination can solve some patient situations of total infertility, subfertility and unexplained infertility. When they first attempt to conceive, most couples experience issues. These couples are inseminated artificially before using IVF. This operation is carried out at home using a semen container kit, syringes, ovulation tests and other assistance products. Some kits include kits for ovulation predictors, as the method is time based on the menstrual cycle of women. In comparison with clinical insemination at home insemination has several benefits. These benefits include partner participation, new sperm use, a relaxed atmosphere, elevated levels of pregnancy and low costs. In most nations artificial insemination is legal but insemination guidelines and rules must be followed.

The report provides analysis of global Artificial Insemination market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.

Market Dynamics

Modern women' s change in their lifestyles, their focus on Planned Parental care, their postponement of child care owing to their continuous careers are important considerations that will drive the development of the worldwide market for artificial insemination. The other variables that could increase market growth in the forecast period 2016-2026 are considerations such as cost efficiency in relation to other fertilization processes and the increasing case of male infertiles. But the worldwide market for artificial insemination faces certain difficulties, including ethics, safety problems and the elevated risk of sexually transmitted diseases transmitted. These variables restrict the use of artificial insemination kits that could restrict the development of the world market for artificial insemination.

Market Insights

Furthermore, the National Health Institutes revealed that about 12 per cent of reproductive age was affected by infertility.

In accordance to' WHO's Reproductive Health Indicators, guidelines to generate, interpret, and analyze worldwide surveillance, the WHO monitors the infertility incidence globally.' The United Nations expects that by 2030 the worldwide rate of fertility will decrease to 2.4% and by 2050, to 2.2%. The insurance for artificial insemination processes is covered in certain nations, including the United States and the United Kingdom.

According to the rules of the National Institute of Health and Clinical Excellence (NICE), homosexual couples should be eligible for fertility. The NHS expects such pairs to be able to take NHS-funded fertility treatments under six self-funded artificial insemination cycles. The first line of infertility therapy is artificial insemination, since it is minimally invasive and cheaper than IVF. Intrauterine insemination was the most prevalent and non-invasive segment in the 2018 era and is probably the fastest-developing market share in the prediction. Due to the greater amount of medical centers providing infertility treatments, fertility clinics retained a major market share in 2018. In 2018, Europe retained a major share of the market. The second largest market in 2018 was North America.

Type Stance

The intrauterine insemination retained the bulk of the market share in 2018. Over the prediction era it is anticipated to be the rapidly growing segment. The most important way to treat infertility is through this mode of insemination, since the pregnancy rate is highest. Moreover, it is a method that is not invasive. The second-largest section of intravaginal (IVI) is expected. IVI can be carried out in fertility clinics or at home, and is preferred in instances of surgery and donor insemination in particular.

End Use Stance

The most significant market share in 2018 is in fertility clinics and is likely to be the fastest growing end-use segment during the forecast era. Due to increasing infertility rates around the globe, the amount of medical facilities providing fertility treatment has risen in recent years. In the fertility clinics all kinds of artificial insemination can be carried out. Most of these processes are done at fertility clinics intrauterine (IUI) and intratubal (ITI). Clinic insemination processes require consulting, which involves determining the ovulation cycle before proceeding. Fertility medicines can also be prescribed by physicians to boost likelihood of conception.

Source Type Insights

The market was resulted by Artificial Husband Insemination (AIH) segment. The most rapid CAGR over the prediction period is also anticipated. Donor insemination (AID) is chosen for pairs with non-viable sperm as a last option. AID may also be chosen by single females or homosexual couples. Donor insemination has proved to be secure as donors ' private medical and extended family history should be provided by sperm banks.

Regional Stance

As the fertility rate in the area decreased over the years, Europe was the biggest national market in 2018. Pregnancy delays and changes in lifestyle are among the variables leading to this decrease. The second-largest market was North America. According to the National Center for Health Statistics, only 62,5 births per 1000 women were reported. Asia Pacific, owing to the growing infertilty rate and the growing awareness of available treatments, is anticipated to be the fastest-growing market in the forecasted years. Countries such as India, China and Brazil, owing to increasing government, increasing health sector and private sector investment, are anticipated to develop at a high pace. However, some of the variables which might hinder the development of artificial insemination kits are unfavorable reimbursement scenarios and increased costs of surgical processes before and after pregnancies.

Market Segmentation

Global Artificial Insemination Market, By Type Outlook

• Intravaginal
• Intracervical
• Intrauterine
• Intratubal

Global Artificial Insemination Market, By End Use

• Home
• Fertility Clinics & Other Facilities

Global Artificial Insemination Market, By Source Type

• AID-Donor
• AIH-Husband

Global Artificial Insemination Market, By Geography

• North America.
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa (MEA)

The market research study on “Artificial Insemination Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Artificial Insemination market segments with market dynamics and their impact. The report also covers basic technology development policies.

This study offers an assessment of the recent industry trends for each sub-segment, from 2015 to 2026. This study forecasts revenues and volume growth at worldwide, regional and nation levels. For this research, on the grounds of the type, end-use, source type and region, ARC segmented a worldwide market for artificial insemination.

Key Players & Strategies

Some of the major companies in the market are FUJIFILM Irvine Scientific; Vitrolife; Genea Limited; Pride Angel; Rocket Medical plc.Hi-Tech Solutions; Rinovum Women’s Health, LLC; KITAZATO CORPORATION.

Companies are concentrating on acquiring tiny companies to enhance their regional presence. For example, JXTGE announced in March 2018 that it has acquisitioned the firm to maximize its synergy and to sustain its biomedical development by selling Irvine Scientific to FUJIFILM. The purchase ended in June 2018.